{"count":5,"limit":50,"offset":0,"edits":[{"id":4963,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-c226f2aa","action":"update","diff_json":{"after":"18b1b72c25b38269985500ad914d7bca1a9f1f3053998c9d37a719e0a545f3fc","before":""},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4964,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-c226f2aa","action":"update","diff_json":{"after":"Combined cystatin-C/TREM2 activation and EC-II SST interneuron gamma gating restores protective inhibition against tau spread. Gamma-frequency entrainment restores perisomatic inhibition that normally contains tau propagation while cystatin-C/TREM2-activated microglia reduce inflammatory load on entorhinal circuit.\n\n## Evidence enrichment addendum: ecii-gamma-oscillation-synergy\n\n        ### Mechanistic focus\n        EC-II SST interneuron gamma gating, cystatin-C/TREM2 microglial support, and tau-spread resistance.\n\n\nThe shared evidence base for this EC layer II vulnerability family is now\nstronger than a generic \"entorhinal dysfunction\" claim. Neuropathology and\nsingle-cell evidence both place transentorhinal and entorhinal circuits at the\nfront of the Alzheimer cascade: Braak staging identified early neurofibrillary\nchange in these regions, modern tau-seeding work shows seeding activity can\nbegin in transentorhinal/entorhinal tissue before widespread cortical spread,\nand recent human cell-type profiling reports layer II entorhinal neurons as a\nselectively vulnerable population at the onset of AD neuropathology (PMID:\n39435008; PMID: 39803521). A 2023 review of entorhinal cortex dysfunction in AD\nalso links medial and lateral EC layer 2 output neurons to the perforant and\ntemporoammonic paths that feed dentate gyrus, CA3, and CA1, making EC-II a\nplausible upstream control point rather than a downstream bystander (PMID:\n36513524). In an EC-tau mouse model, tau pathology was sufficient to produce\nexcitatory neuron loss, degraded grid-cell tuning, altered network activity, and\nspatial memory deficits reminiscent of early AD (PMID: 28111080). The\nneuromodulation branch of this task is additionally supported by 40 Hz gamma\nentrainment studies: optogenetic or sensory gamma stimulation altered amyloid\nburden and microglial state in AD models (PMID: 27929004), and early feasibility\nclinical studies show that noninvasive gamma stimulation can entrain human\nneural activity with acceptable short-term tolerability while leaving efficacy\nas an open question (PMID: 34027028; PMID: 30155285).\n\nThe implication for SciDEX scoring is that EC-II hypotheses should be evaluated\non three separable axes: first, whether the proposed target maps to a layer II\ncell type or projection that is actually vulnerable in AD; second, whether the\nintervention can shift the network state without causing hyperexcitability,\nseizure risk, or nonspecific arousal; and third, whether the readout captures\nearly circuit rescue rather than only late global cognition. Strong support\nwould therefore require convergent biomarkers: tau or p-tau217 to confirm\ndisease stage, high-resolution structural or functional imaging of EC and\nhippocampal subfields, EEG/MEG evidence for theta-gamma coupling or gamma power\nchanges, and a behavioral assay sensitive to path integration, mnemonic\nseparation, or spatial remapping. Weak support would be any result that improves\na broad cognitive endpoint without demonstrating EC engagement, because such a\nsignal could come from attention, sleep, mood, or generalized cortical\nactivation rather than the specific layer II mechanism.\n\n\n        ### Hypothesis-specific interpretation\n        The hypothesis should be interpreted as a two-compartment rescue model: gamma entrainment restores inhibitory timing in EC-II output circuits while cystatin-C/TREM2 signaling improves local proteostasis and phagocytic handling of amyloid or tau-associated debris. This is more defensible than treating gamma as a standalone symptomatic stimulation.\n\n        ### Validation path\n        Prioritize an organoid or slice co-culture assay with SST interneuron activation, microglial state markers, extracellular tau uptake, and network oscillation readouts before moving to closed-loop stimulation in an AD model.\n\n        ### Counterevidence and market caveats\n        The largest risk is causal overreach: gamma entrainment, TREM2 signaling, and cystatin-C biology can each move glial state, but the synergy claim needs factorial testing rather than single-arm improvement. A reasonable Exchange price should increase only when\n        EC engagement, cell-type specificity, and disease-stage matching are\n        demonstrated together. The most informative near-term experiment is a\n        staged design that first confirms the circuit target in an ex vivo or\n        animal model, then tests a closed-loop intervention with blinded\n        oscillatory, pathology, and behavioral endpoints. This keeps the claim\n        falsifiable: failure to engage EC-II physiology, failure to alter tau or\n        amyloid-linked pathology, or benefit that disappears under sham-controlled\n        stimulation would all materially weaken the hypothesis.\n","before":"Combined cystatin-C/TREM2 activation and EC-II SST interneuron gamma gating restores protective inhibition against tau spread. Gamma-frequency entrainment restores perisomatic inhibition that normally contains tau propagation while cystatin-C/TREM2-activated microglia reduce inflammatory load on entorhinal circuit."},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4965,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-c226f2aa","action":"update","diff_json":{"after":0.78,"before":null},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4966,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-c226f2aa","action":"update","diff_json":{"after":"2026-04-20 19:54:50.595930-07:00","before":null},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4967,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-c226f2aa","action":"update","diff_json":{"after":"'/trem2':9,69,504 '/trem2-activated':41 '2':185 '2023':170 '27929004':281 '28111080':250 '30155285':313 '34027028':311 '36513524':216 '39435008':166 '39803521':168 '40':261 'accept':298 'activ':10,132,240,296,465,545 'actual':348 'ad':163,177,248,278,351,565 'addendum':51 'addit':258 'also':178 'alter':238,271,678 'alzheim':114 'amyloid':272,513,682 'amyloid-link':681 'anim':648 'arm':602 'arous':368 'assay':426,541 'associ':517 'attent':459 'axe':331 'base':80 'begin':134 'behavior':425,662 'benefit':686 'biolog':585 'biomark':390 'blind':658 'braak':116 'branch':253 'broad':445 'burden':273 'bystand':214 'c':8,40,68,503,584 'ca1':200 'ca3':198 'captur':374 'cascad':115 'caus':362 'causal':575 'caveat':570 'cell':101,146,236,342,615 'cell-typ':145,614 'chang':121,422 'circuit':48,108,376,499,641 'claim':96,594,667 'clinic':285 'close':560,654 'closed-loop':559,653 'co':539 'co-cultur':538 'cognit':383,446 'combin':5 'come':457 'compart':486 'confirm':397,639 'contain':34 'control':208,692 'converg':389 'cortex':174 'cortic':140,464 'could':456 'counterevid':567 'coupl':418 'cultur':540 'cystatin':7,39,67,502,583 'cystatin-c':6,38,66,501,582 'debri':518 'defens':522 'deficit':244 'degrad':233 'demonstr':449,624 'dentat':196 'design':636 'disappear':688 'diseas':398,620 'disease-stag':619 'downstream':213 'dysfunct':95,175 'earli':119,247,283,375 'ec':13,60,83,183,203,220,322,408,450,496,612,673 'ec-ii':12,59,202,321,495,672 'ec-tau':219 'ecii':53 'ecii-gamma-oscillation-synergi':52 'eeg/meg':412 'efficaci':305 'endpoint':447,663 'engag':451,613,671 'enhanc':3 'enrich':50 'entorhin':47,94,107,152,173 'entrain':28,264,293,490,578 'evalu':327 'evid':49,79,102,413 'ex':645 'exchang':606 'excitatori':230 'experi':632 'extracellular':549 'factori':596 'failur':669,676 'falsifi':668 'famili':87 'feasibl':284 'feed':195 'first':332,638 'focus':58 'frequenc':27 'front':111 'function':405 'gamma':1,17,26,54,64,263,269,290,417,420,489,525,577 'gamma-frequ':25 'gate':18,65 'general':463 'generic':93 'glial':589 'global':382 'grid':235 'grid-cel':234 'gyrus':197 'handl':511 'high':401 'high-resolut':400 'hippocamp':410 'human':144,294 'hyperexcit':363 'hypothes':324 'hypothesi':474,478,699 'hypothesis-specif':473 'hz':262 'identifi':118 'ii':14,61,85,151,204,323,341,471,497,674 'imag':406 'implic':315 'improv':443,506,603 'increas':609 'inflammatori':44 'inform':628 'inhibit':21,31 'inhibitori':492 'integr':430 'interneuron':16,63,544 'interpret':476,481 'intervent':355,656 'keep':665 'largest':572 'late':381 'later':182 'layer':84,150,184,340,470 'leav':304 'link':179,683 'load':45 'local':507 'loop':561,655 'loss':232 'make':201 'map':337 'marker':548 'market':569 'match':622 'materi':696 'mechan':472 'mechanist':57 'medial':180 'memori':243 'microgli':70,275,546 'microglia':42 'mnemon':431 'model':223,279,488,566,649 'modern':125 'mood':461 'mous':222 'move':557,588 'near':630 'near-term':629 'need':595 'network':239,359,553 'neural':295 'neurofibrillari':120 'neuromodul':252 'neuron':153,187,231 'neuropatholog':97,164 'noninvas':289 'nonspecif':367 'normal':33 'onset':161 'open':308 'optogenet':266 'organoid':535 'oscil':2,55,554 'oscillatori':659 'output':186,498 'overreach':576 'p':394 'p-tau217':393 'path':193,429,532 'patholog':225,660,684 'perfor':190 'perisomat':30 'phagocyt':510 'physiolog':675 'place':104 'plausibl':206 'pmid':165,167,215,249,280,310,312 'point':209 'popul':158 'power':421 'price':607 'priorit':533 'produc':229 'profil':148 'project':345 'propag':36 'propos':335 'protect':20 'proteostasi':508 'question':309 'rather':210,378,466,598 'readout':373,555 'reason':605 'recent':143 'reduc':43 'region':124 'remap':435 'reminisc':245 'report':149 'requir':388 'rescu':377,487 'resist':76 'resolut':402 'restor':19,29,491 'result':441 'review':171 'risk':365,573 'scidex':317 'score':318 'second':352 'seed':128,131 'seizur':364 'select':156 'sensit':427 'sensori':268 'separ':330,432 'sham':691 'sham-control':690 'share':78 'shift':357 'short':300 'short-term':299 'show':130,287 'signal':455,505,580 'singl':100,601 'single-arm':600 'single-cel':99 'sleep':460 'slice':537 'spatial':242,434 'specif':469,475,617 'spread':24,75,141 'sst':15,62,543 'stage':117,399,621,635 'standalon':528 'state':276,360,547,590 'stimul':270,291,530,562,693 'strong':384 'stronger':90 'structur':403 'studi':265,286 'subfield':411 'suffici':227 'support':71,259,385,437 'symptomat':529 'synergi':4,56,593 'target':336,642 'task':256 'tau':23,35,74,127,221,224,391,516,550,679 'tau-associ':515 'tau-seed':126 'tau-spread':73 'tau217':395 'temporoammon':192 'term':301,631 'test':597,651 'therefor':387 'theta':416 'theta-gamma':415 'third':370 'three':329 'time':493 'tissu':137 'togeth':625 'toler':302 'transentorhin':105 'transentorhinal/entorhinal':136 'treat':524 'trem2':579 'tune':237 'two':485 'two-compart':484 'type':147,343,616 'upstream':207 'uptak':551 'valid':531 'vivo':646 'vulner':86,157,349 'weak':436 'weaken':697 'whether':333,353,371 'widespread':139 'without':361,448 'work':129 'would':386,438,694","before":"'/trem2':9 '/trem2-activated':41 'activ':10 'c':8,40 'circuit':48 'combin':5 'contain':34 'cystatin':7,39 'cystatin-c':6,38 'ec':13 'ec-ii':12 'enhanc':3 'entorhin':47 'entrain':28 'frequenc':27 'gamma':1,17,26 'gamma-frequ':25 'gate':18 'ii':14 'inflammatori':44 'inhibit':21,31 'interneuron':16 'load':45 'microglia':42 'normal':33 'oscil':2 'perisomat':30 'propag':36 'protect':20 'reduc':43 'restor':19,29 'spread':24 'sst':15 'synergi':4 'tau':23,35"},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"}]}